Alzheimer Disease Vaccine

Anti-A-beta-specific mAbs attenuate amyloid deposition in Alzheimer disease

Published in Vaccine Weekly, March 8th, 2006

Anti-A-beta₄₂ - and anti-A-beta₄₀ -specific monoclonal antibodies (mAbs) attenuate amyloid deposition in an Alzheimer disease mouse model.

"Accumulation and aggregation of amyloid beta peptide 1-42 (A-beta(42)) in the brain has been hypothesized as triggering a pathological cascade that causes Alzheimer disease (AD). To determine whether selective targeting of A-beta₄₂ versus A-beta₄₀ or total A-beta is an effective way to prevent or treat AD, we compared the effects of passive immunization with an anti-A-beta₄₂ mAb, an anti-A-beta₄₀ MAb, and multiple A-beta_1-16 mAbs," scientists in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry